OnKure Therapeutics, Inc. (OKUR) stock
OKURNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.58−0.17 (-6.18%)
Close on Nov 17, 2026Market cap $104.48MP/E –Yield –
OnKure Therapeutics cash
Cash and short-term investments held at the end of each period.
OnKure Therapeutics's cash was $176.40M at Jun 30, 2026. For fiscal 2025 it was $59.05M, down 46.7% from the year before. The highest annual figure on record is $147.67M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.05M | -46.7% |
| FY2024 | Dec 31, 2024 | $110.76M | +5.3% |
| FY2023 | Dec 31, 2023 | $105.21M | +13.4% |
| FY2022 | Dec 31, 2022 | $92.79M | -37.2% |
| FY2021 | Dec 31, 2021 | $147.67M | +175.4% |
| FY2020 | Dec 31, 2020 | $53.61M | +206.3% |
| FY2019 | Dec 31, 2019 | $17.50M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $176.40M | +111.6% |
| Q1 FY2026 | Mar 31, 2026 | $192.11M | +98.7% |
| Q4 FY2025 | Dec 31, 2025 | $59.05M | -46.7% |
| Q3 FY2025 | Sep 30, 2025 | $70.33M | -8.3% |
| Q2 FY2025 | Jun 30, 2025 | $83.37M | +40.5% |
| Q1 FY2025 | Mar 31, 2025 | $96.66M | +18.3% |
| Q4 FY2024 | Dec 31, 2024 | $110.76M | +5.3% |
| Q3 FY2024 | Sep 30, 2024 | $76.70M | -38.9% |
| Q2 FY2024 | Jun 30, 2024 | $59.34M | -58.4% |
| Q1 FY2024 | Mar 31, 2024 | $81.71M | -12.9% |
| Q4 FY2023 | Dec 31, 2023 | $105.21M | +13.4% |
| Q3 FY2023 | Sep 30, 2023 | $125.61M | +8.2% |
| Q2 FY2023 | Jun 30, 2023 | $142.68M | +12.5% |
| Q1 FY2023 | Mar 31, 2023 | $93.79M | -32.4% |
| Q4 FY2022 | Dec 31, 2022 | $92.79M | -37.2% |
| Q3 FY2022 | Sep 30, 2022 | $116.08M | -26.4% |
| Q2 FY2022 | Jun 30, 2022 | $126.85M | -24.2% |
| Q1 FY2022 | Mar 31, 2022 | $138.66M | +52.0% |
| Q4 FY2021 | Dec 31, 2021 | $147.67M | +175.4% |
| Q3 FY2021 | Sep 30, 2021 | $157.73M | +1231.7% |
| Q2 FY2021 | Jun 30, 2021 | $167.33M | +923.9% |
| Q1 FY2021 | Mar 31, 2021 | $91.22M | +399.0% |
| Q4 FY2020 | Dec 31, 2020 | $53.61M | +206.3% |
| Q3 FY2020 | Sep 30, 2020 | $11.85M | – |
| Q2 FY2020 | Jun 30, 2020 | $16.34M | – |
| Q1 FY2020 | Mar 31, 2020 | $18.28M | – |
| Q4 FY2019 | Dec 31, 2019 | $17.50M | – |
See a number that looks wrong?